Tazarotene is under clinical development by GRI Bio and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tazarotene’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tazarotene overview
GRI-0621 is under development for the treatment of idiopathic pulmonary fibrosis. The therapeutic candidate is a gel capsule formulation administered through the oral route. It acts by targeting RAR-beta and RAR-gamma. It was under development for the treatment of non-alcoholic steatohepatitis, alcoholic steatohepatitis (ASH), viral hepatitis and chronic liver disease.
GRI Bio overview
GRI Bio is a clinical-stage biopharmaceutical company. It focuses on developing NKT cell-based therapies for treatment of inflammatory, fibrotic, and autoimmune diseases. The company’s product pipeline includes GRI 0621, novel oral therapeutic to treat idiopathic pulmonary fibrosis; GRI 0803, treatment of systemic lupus erythematosus (SLE). The company also investigates GRI 0729, a type 2 NKT agonist drug program at pre-clinical stage. GRI Bio is headquartered in La Jolla, California, the US.
For a complete picture of Tazarotene’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
